MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Craig-Hallum Capital Group 14th Annual Alpha Select Conference
Thursday, November 16, 2023
Sheraton New York Times Square Hotel
811 7th Avenue, W 53rd St
New York, NY
Mizuho Medical Device & Healthcare Services Summit 2023
Wednesday, December 6, 2023
Sofitel New York
45 W 44th St
New York, NY
Stifel MedTech 2023 Annual West Coast Bus Tour
Thursday, December 14, 2023
Four Seasons Palo Alto
2050 University Ave
East Palo Alto, CA
Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Mizuho, or Stifel representative.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.50 |
| Daily Change: | 0.19 2.60 |
| Daily Volume: | 1,051,781 |
| Market Cap: | US$1.100B |
February 28, 2024 | |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
